Startups

Scripta Therapeutics

Scripta Therapeutics is an Oxford-based techbio company combining AI and machine learning, imaging, bioinformatics and patient-derived experimental models to discover molecules that modulate transcription-factor activity. Its approach maps disease-related transcriptional networks and validates proposed interventions in experimental models. Initial research focuses on Alzheimer's disease, Parkinson's disease and ALS; disease-modifying efficacy is a research objective, not an established clinical or regulatory claim. Founder and CEO Peter Hamley leads a published scientific team with Jerry Huang, Andy Walker, John Blackwood and academic co-founder Noel Buckley. The current site identifies Raymond Barlow, Claire Brown and Marianne Mertens in its board section; Mertens' exact director-versus-observer status is unspecified. The issuer announced USD12million seed funding on November14,2025, jointly led by Oxford Science Enterprises and Apollo Health Ventures with AlbionVC, YZR Capital and Parkwalk Advisors participating. Oxford University Innovation is described as supporting the company, which alone does not prove a cash investment. The retained seed record dates November13,2025 from an earlier secondary article; that date is not asserted as an independently verified closing day. Public team publication does not establish the full private employee roster.